Saturday 17 October 2026
Export IMCR’s income statement to Excel — free account
Immunocore Holdings PLC Sponsored ADR
IMCR Healthcare Biotechnology
Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024. In the quarter to June 2026, revenue grew 18.3%, EPS grew 92.1%, free cash flow fell 40.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years.
29.40
0.08
−0.27%
Follow IMCR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.76 | 3.71 | 4.37 | 4.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 612.02 | |
P/Operating CF |
101.61 | (111.09) | (53.51) | (410.95) | |
P/B ratio |
3.86 | 3.89 | 4.59 | 4.62 | |
Price to Tangible BV |
3.87 | 3.91 | 4.61 | 4.64 | |
EV/Sales |
2.74 | 2.73 | 3.31 | 3.63 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(33.77) | (45.23) | (123.66) | 172.62 | |
EV/FCF |
(28.69) | (36.66) | (88.01) | 461.10 | |
Quick Ratio |
4.15 | 3.86 | 3.80 | 5.68 | |
Current Ratio |
4.47 | 4.18 | 4.04 | 6.00 | |
Net Debt/EBITDA |
246.70 | (54.84) | 24.98 | 78.42 | |
Debt/Assets |
35.22% | 36.72% | 36.83% | 35.61% | |
Debt/Equity |
0.94 | 1.00 | 1.03 | 0.99 | |
Asset Turnover |
0.39 | 0.39 | 0.39 | 0.35 | |
Operating CF/Net income |
(19.71) | (1.06) | 1.09 | 25.18 | |
Capex/Depreciation |
(0.77) | (1.88) | (3.45) | (0.94) | |
Interest Coverage |
(0.98) | 2.39 | (6.45) | (2.36) | |
Research and Development Expense of Revenue |
63.79% | 57.29% | 75.44% | 68.06% | |
Selling, General and Administrative Expense of Revenue |
37.86% | 35.48% | 40.82% | 38.36% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
8.11% | 5.91% | 7.98% | 9.49% | |
Graham Net Nets |
0.22 | 0.21 | 0.18 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.13%) | (1.80%) | (2.03%) | (1.58%) | |
Free Cash Flow Yield |
(2.54%) | (2.01%) | (0.86%) | 0.16% | |
Revenue per Share |
2.27 | 2.10 | 2.08 | 2.06 | |
Operating CF per Share |
0.31 | (0.27) | (0.65) | (0.09) | |
Capex per Share |
(0.02) | (0.04) | (0.06) | (0.01) | |
Free Cash Flow per Share |
0.30 | (0.31) | (0.71) | (0.10) | |
Cash per Share |
17.27 | 16.65 | 17.16 | 17.70 | |
Shareholders Equity per Share |
8.24 | 7.76 | 7.57 | 7.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.24 | 7.76 | 7.57 | 7.87 | |
Free Cash Flow |
15.14 | (15.56) | (35.53) | (5.20) | |
Working Capital |
815.85 | 763.69 | 750.05 | 852.50 | |
Capital Expenditures |
(0.79) | (1.78) | (2.88) | (0.75) | |
Net Current Asset Value |
351.42 | 325.39 | 310.51 | 316.91 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.03 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
82.56 | 72.08 | 68.49 | 69.77 | |
Average Payables |
25.09 | 29.63 | 24.73 | 21.34 | |
Average Inventory |
6.62 | 7.53 | 6.09 | 5.09 | |
Average Assets |
1,100.90 | 1,050.05 | 1,038.39 | 1,093.57 | |
Average Common Equity |
404.14 | 386.08 | 370.87 | 387.20 |
Columns are period end dates